Sotorasib (AMG 510) Precision Cancer Medicine Targets KRAS NSCLC


by Dr. C.H. Weaver M.D. 2/2021

Decades of research may have finally determined how to target KRAS, a major genetic driver of lung and other cancers. Initial study results presented at the American Society of Clinical Oncology's annual meeting in Chicago revealed that the novel precision cancer medicine currently known as Sotorasib “AMG 510” caused five of 10 lung cancers to shrink and follow up data has expanded and confirmed these encouraging results. (1,2)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Sotorasib, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation, as determined by an FDA-approved test, following at least one prior systemic therapy.

Results from the CodeBreaK 100 clinical study, evaluating Sotorasib in 126 patients with KRAS G12C-mutant advanced non-small cell lung cancer NSCLC, who had failed a median of two prior lines of anti-cancer therapies are reported to be positive and were released at the IASLC 2020 World Congress on Lung Cancer taking place January 2021 and confirmed a 37% response rate. (4)

KRAS is an oncogene that impacts the growth of lung, pancreatic and colorectal cancers. AMG510 is the first medication of its kind to reach clinical testing and binds to mutated KRAS protein which “turns off” the signals it sends to trigger cell division and cancer cell growth.

Sotorasib irreversibly inhibits KRAS G12C by permanently blocking it in an inactive GDP-bound state and represents a first-in-class novel small molecular inhibitor that specifically binds to a mutant protein in KRAS. G12C occurs in roughly 13% of NSCLC's, 3% to 5% of colorectal cancers, and between 1% and 3% of other cancers.

Among 10 NSCLC patients with the KRAS G12C mutation confirmed by gene sequencing five individuals experienced a partial response to therapy and four had stable disease. All patients who responded remain on therapy with follow-up stretching from seven weeks to more than six months. Interestingly, results didn't appear as positive in colorectal cancer, however, where 13 of 18 evaluable patients had stable disease.

In a second report researchers assessed AMG 510 in a basket trial of 76 patients with locally advanced or metastatic KRAS G12C-mutant solid tumors who had progressed on standard therapy. Their analysis includes a subset of 34 patients with NSCLC, 23 of whom were evaluable for efficacy.

Although the primary objective of the trial was to asses safety and dosing 96% of patients achieved disease control, with a 48% overall response rate. The majority of patients experienced partial response, observed as early at about 6 weeks.The drug was well-tolerated, with no dose-limiting toxicities reported to date.

A Little More Information About the KRAS Oncogene

A pivotal milestone in cancer research was the discovery of a group of genes called the RAS family. RAS is an oncogene—a gene that encodes proteins that function as switches to turn on various genes for cell growth and division. These genes are intricate players in the normal cell cycle, responding to cues both outside and inside the cell that regulate how fast a cell should grow and divide. Furthermore, there are myriad proteins that interact with RAS—including receptors on the cell surface—that pass signals into the cell through complex circuits of protein interactions, with the end result being changes in gene expression. Mutations in the RAS genes result in permanently “turned on” switches that in turn result in uninhibited cell division, which can lead to cancer.

There are three types of RAS oncogenes, designated NRAS, GRAS, and KRAS. Although mutations in all three can cause cancer, KRAS is the most frequently mutated oncogene in human colorectal cancer. About 40 to 50 percent of human colorectal cancers have mutated KRAS genes. Recently developed laboratory assays are able to differentiate those tumors that have this mutation from those that have normal (also called wild-type) KRAS.

This has had several therapeutic implications. Cancers that have non-mutated, or wild-type, KRAS are susceptible to a class of biologic agents called epidermal growth factor receptor (EGFR) inhibitors. EGFR is a receptor on the surface of the cell that binds to a growth factor called epidermal growth factor (EGF). This receptor activates cellular pathways that promote cell growth and division, with KRAS being one of the key players in the process. Blocking the EGF receptor removes this important signal for the continued growth of cancer cells. The two EGFR-targeting agents studied in colon cancer are Erbitux® (cetuximab) and Vectibix (panitumumab).

Another exciting group of drugs that specifically targets the KRAS protein works by inhibiting an enzyme called farnesyltransferase. This enzyme is involved in activating the RAS proteins. As of yet these drugs are not available for use at the bedside and are currently being tested in animal models.

Other cancers also express the KRAS G12C Mutation


  2. Fakih M, et al. Abstract 3003. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
  3. Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation
  4. Amgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer